Log in
Hong Kong S.A.R
China is back, or what? China is back, or what? China is back, or what?

China is back, or what?

Equities 4 minutes to read
Peter Garnry

Chief Investment Strategist

Key points

  • China pulls out the big bazooka: China boosts its economy with stimulus measures, including support for the stock market and lower interest rates, raising questions about long-term effectiveness.

  • Micron earnings and growth: Micron's positive outlook signals strong growth tied to AI and a future recovery in the PC market.

  • Health care as a growth sector: The health care sector has historically outperformed the market, driven by innovation, patents, and AI, positioning itself as both a growth and defensive sector.

  • Upcoming events: Key events include Nike's earnings, German inflation, and the US jobs report, which could impact market expectations.

China pulls out the big bazooka

Chinese equities traded in Hong Kong are up 20% from their lows earlier this month as the Chinese government pulled out the stimulus bazooka including support for the stock market. The People’s Bank of China has also recently lowered key benchmark rates and other measures have been implemented to shore the distress in the Chinese property sector. In the short-term, tactical traders and momentum chasing investors are bidding up Chinese equities, but for the long-term investor the fundamental question is different. Is this enough to break the downward spiral from its balance sheet recession that China is facing.

The excessive private sector debt in China means that lower interest rates may not solve anything like the developed world learned in the aftermath of the Great Financial Crisis. For China the problem is even bigger. China’s pension age is 60 and the dependency ratio was 46.6% in 2022 and is expected to surge in the years to come. That means a larger part of the population will live from passive income and thus lower interest rates will both suppress passive income for the elderly non-working population, but for the working population higher savings rate is needed to generate a meaningful passive income in the future. That could lower consumption in the economy and make it more difficult to get out of the balance sheet recession.

Some of the best performing Chinese stocks in the Hang Seng Index, the leading Hong Kong benchmark index, are Meituan and JD.com reflecting increased expectations for higher consumer spending. In Europe, we have seen similar reaction in luxury stocks such as LVMH.

Chinese equities | Source: Saxo

What does Micron earnings tell us about growth?

Micron Technology reported a better-than-expected outlook on Wednesday due to the boom in AI. The DRAM memory chip market is booming with tight supply driving prices higher and the chipmaker expects unit growth again in the global PC market in 2025. Micron Technology has always had a strong correlation to the global economic growth cycle. An upbeat outlook from Micron is a positive macro indicator.

Health care as a growth sector

On Wednesday, I did a presentation on the global health care sector for some our clients. The other presenters were Claus Henrik Johansen, Chief Investment Officer, at Global Health Invest which is a new mutual fund expected to IPO 1 November 2024 on Nasdaq Copenhagen. Claus comes with 20 years of experience in the health care sector as a senior portfolio manager at Danske Bank Asset Management. The last presenter was Henning Langberg giving insights into how technology, including AI, is already being implemented in the Danish health care sector and what the potential is for productivity gains in the future.

I could write for an hour of all things I learned, but some of the key take-ways were the following:

  • The global health care sector is a growth sector
  • It has outperformed the global equity market by 1.5% annualized since July 2000
  • It has lower drawdowns that the global equity market during crises and recessions
  • The sector enjoys competitive advantages through patents and R&D investments
  • AI is going to play a crucial role in drug discovery and health care services
  • We will all get a health care digital-twin
  • Apple is going to be a key player in the future health care sector

One of the key charts that I showed was the one below. It shows the revenue per share cumulative growth over the past 10 years. The key insight here is the remarkable consistency in growth and its extremely low sensitivity to the economic cycle. In other words, the global health care sector is both a growth and defensive sector at the same time, which is a very unique characteristic not shared by many other sectors or industries.

The week ahead: Nike earnings, German inflation, and US jobs report

  • Earnings: The key earnings to watch in the week ahead are Nike (Tuesday, aft-mkt) and Carnival (Monday, bef-mkt) with Nike earnings expected to pull the most attention from investors. Nike has had a rough past year rallying hard in late 2023 before entering 2024 with a lot of hiccups including the worse-than-expected outlook announced back in June. Analysts expect Nike to report FY25 Q1 (ending 31 August) revenue of €11.7bn down 10% YoY as Nike right now have a product gap relative to Adidas in sports fashion shoes, which is also why Nike has emphasized that it wants to speed up innovation. The new CEO, Nike veteran Elliott Hill, has a steep journey ahead of him to turn around Nike.

  • German inflation: The report is out on Monday with economists expecting German inflation to hit 1.7% YoY for September down from 1.9% YoY in August. This should provide the ECB with more room for lowering the policy rate despite the central bank’s worries over elevated wage growth in the Eurozone. The is now pricing 80% probability that the ECB cuts its policy rate at the next meeting on 17 October up from 50% probability the day after the last ECB rate decision on 12 September.

  • US jobs report: On Friday the US jobs report will add another layer to the US labour market picture which is the new focus of the Fed. We know from the JOLTS job openings report (out this Wednesday) that the labour market is a lot less tight than a year ago, but the weekly time series from Indeed shows that the US labour market is stabilizing. Economists expect the US jobs report to show a gain of 140k in September on par with the gain for August at 142k. Traders will also focus on the average hourly earnings figures for clues about the outlook for consumer spending.

Previous weekly equity market updates

Quarterly Outlook 2024 Q3

Sandcastle economics

01 / 05

  • Macro: Sandcastle economics

    Invest wisely in Q3 2024: Discover SaxoStrats' insights on navigating a stable yet fragile global economy.

    Read article

  • Bonds: What to do until inflation stabilises

    Discover strategies for managing bonds as US and European yields remain rangebound due to uncertain inflation and evolving monetary policies.

    Read article

  • Equities: Are we blowing bubbles again

    Explore key trends and opportunities in European equities and electrification theme as market dynamics echo 2021's rally.

    Read article

  • FX: Risk-on currencies to surge against havens

    Explore the outlook for USD, AUD, NZD, and EM carry trades as risk-on currencies are set to outperform in Q3 2024.

    Read article

  • Commodities: Energy and grains in focus as metals pause

    Energy and grains to shine as metals pause. Discover key trends and market drivers for commodities in Q3 2024.

    Read article
Disclaimer

The Saxo Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo or its affiliates.

Saxo Capital Markets HK Limited
19th Floor
Shanghai Commercial Bank Tower
12 Queen’s Road Central
Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R
Products & pricing
Asset Management
Platforms
Accounts & service
General
Other
Legal

Losses can exceed deposits on margin products. Please ensure you understand the risks.

Saxo Capital Markets HK Limited (“Saxo”) is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo holds a Type 1 Regulated Activity (Dealing in Securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged Foreign Exchange Trading); Type 4 Regulated Activity (Advising on Securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products may result in your losses exceeding your initial deposits. Saxo does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo does not take into account an individual’s needs, objectives or financial situation. Please click here to view the relevant risk disclosure statements.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-hk/about-us/awards.

The information or the products and services referred to on this site may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and services offered on this website are not directed at, or intended for distribution to or use by, any person or entity residing in the United States and Japan. Please click here to view our full disclaimer.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc. Android is a trademark of Google Inc.